Rice Hall James & Associates’s Soleno Therapeutics SLNO Stock Holding History

Rice Hall James & Associates’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-206,147	Closed	-$6.9M	–	252
2026 Q1	$6.9M	Buy	+206,147	New	+$8.08M	0.38%	69

Rice Hall James & Associates's SLNO Position: Q2 2026 in Review

Rice Hall James & Associates sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 206,147 shares — an estimated $6.9M sold.

Rice Hall James & Associates first reported a position in SLNO in Q1 2026 and held it in 1 quarter. The position peaked at $6.9M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Rice Hall James & Associates reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Rice Hall James & Associates sold 206,147 Soleno Therapeutics shares in Q2 2026, an estimated $6.9M.
Rice Hall James & Associates first reported a position in Soleno Therapeutics in Q1 2026 and held it in 1 quarter.
Rice Hall James & Associates's Soleno Therapeutics position peaked at $6.9M in Q1 2026.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.